Accelerating CRO Study Deployment At Scale

A leading top-3 CRO and a top-10 pharmaceutical company joined forces with Medable to transform their eCOA trial operations, overcoming lengthy setup times, fragmented designs, and disjointed sponsor–CRO workflows. By consolidating the sponsor’s preferred instruments and configurations into a centralized, reusable digital library, Medable enabled the CRO to spin up new studies in days rather than weeks—accelerating first-patient-in dosing and supporting multiple concurrent trials without extra manpower.

Medable’s scalable deployment model—anchored by its Studio self-serve environment, AI-driven compliance and translation tools, and single-sign-on workspace—streamlined build, test, and iteration cycles. As a result, the CRO secured a competitive advantage with transparent pricing and repeatable processes, while the sponsor achieved aggressive portfolio milestones on schedule and at scale. Key innovations included parallel study builds using shared templates (launching multiple trials within weeks), condensed design reviews (two focused sessions replacing three-week meeting schedules), and harmonized eCOA interfaces across all programs. These enhancements cut cycle times, reduced rework, and elevated data quality, site onboarding, and patient experience.

This three-way partnership set a new benchmark in eCOA delivery: a unified digital foundation that aligns stakeholders, accelerates timelines, and maintains high-quality, patient-centric trials—turning previous bottlenecks into competitive advantages.